Eruptive melanocytic nevi associated with ponatinib

Ponatinib (ICLUSIG, Takeda; Osaka, Japan) is an oral third-generation tyrosine kinase inhibitor (TKI) approved by US Food and Drug Administration in 2012 used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL), for whom no other tyrosine kinase inhibitor therapy is indicated, and for patients with T3151+ CML or T315I Ph+ ALL.1 Skin rash and dry skin are the most frequent dermatologic adverse effects, reported as high as 34% and 32%, respectively.1 Recently, pityriasiform and ichthyosiform cutaneous toxicities were also reported, sometimes associated with eyebrow alopecia.2 Here, we report the first case, to our knowledge, of eruptive melanocytic nevi (EMN) induced by ponatinib, an adverse effect previously reported with a few other TKI.